Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.

This article reviews various hair growth and hair loss treatments, noting limited new developments since FDA-approved drugs but highlights recent cosmetic surgery and potential cell-based therapies; it reports no original findings.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

This study reviewed existing methods to prevent chemotherapy-induced hair loss, highlighting FDA-approved scalp cooling as currently the most effective yet still insufficient solution and noting the need for more reliable treatments to better support cancer patients.

This review outlines current treatments for androgenetic alopecia, highlighting the efficacy and side effects of FDA-approved options like minoxidil and finasteride, and emphasizes the necessity of long-term use and careful patient collaboration to avoid adverse reactions.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

This chapter reviews treatment options for androgenetic alopecia, noting FDA-approved finasteride and minoxidil for stabilizing or improving scalp coverage, positive off-label results with platelet-rich plasma, and effectiveness of hair transplantation using healthy follicular units.

In this study, researchers used a computational drug repurposing approach to identify FDA-approved drugs Dutasteride and Solifenacin as potential inhibitors of Listeria monocytogenes via binding to the virulence factor regulator PrfA, suggesting they may offer new treatment strategies against multi-drug resistant strains.

This review discusses the increased prevalence of androgenic alopecia in men and women, highlighting the limited FDA-approved treatment options, and reports no clinical results; the authors note adherence challenges due to prolonged drug use.

This article reviews current diagnostic methods and treatments for hair loss, including FDA-approved drugs and surgical options, but reports no new research findings.

This review summarizes existing knowledge on diffuse and patterned alopecia, emphasizing recent advancements in treatment beyond FDA-approved options, but it reports no new clinical findings.

This article reviews the available data on artificial hair fibers, noting FDA bans and reported side effects, without presenting new research findings.

This review discusses various treatments for androgenic alopecia, highlighting FDA-approved options and other commonly used therapies, but reports no new clinical results.

This review discusses the treatment options for male androgenetic alopecia, including FDA-approved therapies and new possibilities, but reports no new clinical results.

This review discusses the characteristics and management of adolescent androgenetic alopecia, noting a lack of FDA-approved treatments and reporting no new clinical results.

This review discusses male androgenetic alopecia treatments, noting that topical minoxidil and oral finasteride are FDA-approved and require continuous use to maintain hair retention effects, but reports no new clinical results.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

This article discusses systemic lupus erythematosus, covering its clinical features, treatments, and the recent FDA approval of belimumab, but does not present new clinical results.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review focuses on neuroactive steroids' influence on GABA-ergic signaling and discusses challenges in developing them for various therapeutic uses, citing recent excitement from FDA approval of allopregnanolone for postpartum depression but reporting no new results.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

This review examines mesotherapy for local fat reduction, detailing its mechanisms, safety concerns, and the need for research toward FDA-approved uses, but reports no new clinical findings.

This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.

This study developed two comprehensive patient-reported outcome measures for systemic lupus erythematosus to assess symptom fluctuations and impacts, following FDA guidelines, which may aid in clinical studies and practice.

This abstract explains that androgenetic alopecia, a common hair loss disorder influenced by genetics and hormones like dihydrotestosterone, has FDA-approved treatments including minoxidil, finasteride, and photolaser therapy, but its genetic basis and susceptibility to environmental factors remain complex.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

The document discusses male and female pattern hair loss, its diagnosis methods, FDA-approved treatments like finasteride and minoxidil, their side effects, and the role of lifestyle changes.

In this study, clinically used preoperative skin preparations with povidone iodine and chlorhexidine gluconate did not meet FDA log-reduction standards for bacterial bioburden in a porcine model, suggesting persistent infection risks.